Finding new targets for immunotherapy in Multiple Myeloma
Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma
This study is looking for new ways to treat Multiple Myeloma by finding specific proteins on cancer cells that could help create better immunotherapies, with the hope of helping patients stay in remission longer after their current treatments.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10979960 on NIH RePORTER |
What this research studies
This research focuses on improving treatments for Multiple Myeloma, a type of blood cancer. The team is using advanced techniques like mass spectrometry and RNA sequencing to identify specific proteins on the surface of cancer cells that could be targeted by new immunotherapies. By analyzing samples from over 900 patients and various cancer cell lines, they aim to discover novel targets that could lead to more effective treatments. The goal is to enhance the duration of remission for patients who have already undergone other therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with relapsed or refractory Multiple Myeloma who have previously undergone treatment.
Not a fit: Patients with early-stage Multiple Myeloma or those who have not received prior treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with Multiple Myeloma, potentially extending remission periods.
How similar studies have performed: Previous research has shown promise in targeting B-cell maturation antigen (BCMA) in Multiple Myeloma, indicating that exploring new targets could also yield successful outcomes.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Perna, Fabiana — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Perna, Fabiana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.